Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7795081 + itraconazole refers to the co-administration of the investigational compound RO7795081 (also known as RG6356) and the antifungal agent itraconazole in clinical pharmacology studies. RO7795081 is a small molecule antagonist of the G protein-coupled receptor 55 (GPR55), developed by Roche as a potential dystrophin-independent therapy for Duchenne muscular dystrophy (DMD). The combination was specifically utilized in Phase 1 drug-drug interaction (DDI) trials to evaluate the effect of itraconazole, a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme, on the pharmacokinetics and safety profile of RO7795081. In late 2022, Roche announced the discontinuation of the RO7795081 (RG6356) program following a review of clinical data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RO7795081 + itraconazole.